Live Report from ASH:
Interleukin-2 For Acute Myeloid Leukemia In First Remission?

Live Report from ASH:
Interleukin-2 For Acute Myeloid Leukemia In First Remission?

 
 
00:00 /
 
1X
 
Jonathan Kolitz
Jonathan Kolitz

JONATHAN KOLITZ, Monter Cancer Center, Lake Success, NY
GEORGE CANELLOS, Dana-Farber Cancer Institute
For patients with acute myeloid leukemia in first remission, new data suggests that there may be a benefit from interleukin-2. Derek Thorne got the interim results of this phase III trial from Jonathan Kolitz of Monter Cancer Center, Lake Success, NY, while George Canellos of the Dana-Farber Cancer Institute provided comment.

Live Report from ASH:<br />Interleukin-2 For Acute Myeloid Leukemia In First Remission?
[audio:https://www.audiomedica.com/podcasting/oncology/071209_jonathan_kolitz.mp3]

You may also like...

Leave a Reply

Your email address will not be published. Required fields are marked *